Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Novel Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05632484
What this trial is testing

Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia

Who this might be right for
Hereditary Haemorrhagic Telangiectasia
Hospices Civils de Lyon 16
Early research (Phase 1)Study completedNCT06001671
What this trial is testing

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

Who this might be right for
NSCLC
Hunan Province Tumor Hospital 23
Not applicableUnknownNCT03597958
What this trial is testing

Genetic Causes of Hypercholesterolaemia in the Emirati Population

Who this might be right for
Familial Hypercholesterolemia
Imperial College London Diabetes Centre 1,000
Large-scale testing (Phase 3)Study completedNCT02987543
What this trial is testing

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 387
Testing effectiveness (Phase 2)Ended earlyNCT04566133
What this trial is testing

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Who this might be right for
Bile Duct CancerBiliary CancerBiliary Tract Neoplasms+1 more
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT03047213
What this trial is testing

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaMetastatic Transitional Cell CarcinomaMetastatic Urothelial Carcinoma+3 more
National Cancer Institute (NCI) 17
Not applicableStudy completedNCT03493230
What this trial is testing

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )

Who this might be right for
Malignant Melanoma Stage IVMalignant Melanoma Stage III
Centre Hospitalier Universitaire de Nice 35
Not applicableUnknownNCT05196243
What this trial is testing

Multimodal Imaging Based on Pathological and Genomic Characteristics

Who this might be right for
Mitochondrial DNA MutationEndoscopy
Affiliated Hospital to Academy of Military Medical Sciences 200
Not applicableStudy completedNCT00723567
What this trial is testing

A Novel Mutation of the Spectrin Gene

Who this might be right for
Hereditary Elliptocytosis (HE)Hereditary Pyropoikilocytosis (HPP)
University of Utah 12
Not applicableLooking for participantsNCT04258449
What this trial is testing

DOvEEgene Fleur: New Uterine Sampling Tool

Who this might be right for
Women With Suspected or Confirmed Gynecological Disease
McGill University 40
Not applicableLooking for participantsNCT00697411
What this trial is testing

Study of Selected X-Linked Disorders: Aicardi Syndrome

Who this might be right for
Aicardi SyndromeBrain Disorders
Baylor College of Medicine 500
Early research (Phase 1)Study completedNCT02729298
What this trial is testing

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal Carcinoma+2 more
Sumitomo Pharma America, Inc. 177
Testing effectiveness (Phase 2)Active Not RecruitingNCT03381274
What this trial is testing

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedImmune LLC 43
Not applicableStudy completedNCT02841085
What this trial is testing

New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".

Who this might be right for
Thromboembolic Venous Disease
University Hospital, Brest 613
Not applicableStudy completedNCT00582335
What this trial is testing

Identification of New Colorectal Cancer Genes

Who this might be right for
Colorectal Cancer
Memorial Sloan Kettering Cancer Center 337
Early research (Phase 1)WithdrawnNCT02758730
What this trial is testing

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

Who this might be right for
Parkinson's Disease
Affiris AG
Not applicableUnknownNCT03589079
What this trial is testing

Delineation of Novel Monogenic Disorders in the United Arab Emirates Population

Who this might be right for
Mendelian DisordersGenetic DisorderNovel Mutation+4 more
Imperial College London Diabetes Centre 150
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Not applicableLooking for participantsNCT07085533
What this trial is testing

Natural History Study of Inherited Retinal Diseases

Who this might be right for
Retinal DystrophiesColor Vision DefectsVision Disorders+7 more
Zhongmou Therapeutics 200
Testing effectiveness (Phase 2)Looking for participantsNCT07451912
What this trial is testing

Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

Who this might be right for
Acute Myeloid Leukemia (AML)CEBPA MutationUnfit, New-diagnosis AML
The First Affiliated Hospital of Soochow University 29
Next Page